John Overdeck’s Scinai Immunotherapeutics SCNI Stock Holding History

John Overdeck’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27	Closed	-$76K	–	4203
2020 Q4	$76K	Buy	+27	New	+$327K	﹤0.01%	3228

Other funds holding SCNI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

John Overdeck's SCNI Position: Q1 2021 in Review

John Overdeck sold out of Scinai Immunotherapeutics (SCNI) in Q1 2021, closing a stake of 27 shares — an estimated $76K sold.

John Overdeck first reported a position in SCNI in Q4 2020 and held it in 1 quarter. The position peaked at $76K in Q4 2020. 16 funds tracked by Wall St. Rank hold SCNI as of Q1 2021.

John Overdeck reported no remaining Scinai Immunotherapeutics position as of Q1 2021 after selling out during the quarter.
John Overdeck sold 27 Scinai Immunotherapeutics shares in Q1 2021, an estimated $76K.
John Overdeck first reported a position in Scinai Immunotherapeutics in Q4 2020 and held it in 1 quarter.
John Overdeck's Scinai Immunotherapeutics position peaked at $76K in Q4 2020.
16 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2021.

Based on Two Sigma Investments's 13F filing for Q1 2021, filed 17 May 2021.